Malignant Tumor Clinical Trial
Official title:
A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
To evaluate the safety of therapeutic immunological agent against EBV-positive advanced malignancies, examining the incidence, type of occurrence, and severity of adverse events in relation to the agent tested, and initially exploring the effectiveness of the immunological agent.
EBV (Epstein-Barr virus) is the first tumor-associated virus to be discovered, closely related to a variety of malignant tumors, including nasopharyngeal carcinoma (NPC), a variety of lymphomas, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), Burkitt's lymphoma (BL) and partial EBV positive stomach cancer (EBV-associated Gastric Carcinomas, EBVaGC). Treatment of the above EBV+ tumors, surgery, radiotherapy and chemotherapy are still the main methods, immunotherapy for some patients has shown good efficacy, prolonging the patient's overall survival rate (Overall Survival, OS) and progression-free survival rate (Progression-Free-Survival, PFS), but the overall clinical efficacy needs to be further improved, and new treatment methods are urgently needed. After tumor cells are infected with EBV virus, they will express a variety of EBV virus antigens, which these proteins can promote the transformation and proliferation of human cells, inhibit cell apoptosis and participate in the occurrence and development of tumors, which also become candidate targets for research of immunotherapy because of the strong antigenicity of viral antigens. Therapeutic immunological agent was prepared which are naturally loaded with EBV antigens and present them to activate T cells and dendritic cells(DC) in vitro and significantly inhibit tumor growth in vivo. The agent also showed good safety. According to these findings suggest the therapeutic immunological agent provides a new idea for immunotherapy of EBV-related tumors. The findings suggest that a number of patients with malignant tumors who failed EBV+ multi-line therapy, including nasopharyngeal cancer, NK/T lymphoma, and gastric cancer needed to be treated with new immunotherapy method to achieve better outcomes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04691349 -
CAR-T for r/r Malignant Tumors in Children
|
Early Phase 1 | |
| Recruiting |
NCT04672473 -
Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06080984 -
The Application of Novel Oncolytic Virus in Late Stage Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04991506 -
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02552004 -
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study
|
N/A | |
| Recruiting |
NCT05280873 -
Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP
|
Phase 1 | |
| Completed |
NCT06093945 -
Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT05592262 -
Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03012945 -
Epidural Anesthesia-analgesia and Long-term Outcome
|
N/A | |
| Recruiting |
NCT04686682 -
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06084767 -
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
|
N/A | |
| Enrolling by invitation |
NCT02937246 -
Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction
|
N/A | |
| Completed |
NCT03354741 -
Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children
|
N/A | |
| Recruiting |
NCT03931720 -
Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor
|
Phase 1/Phase 2 | |
| Completed |
NCT01906632 -
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
|
N/A | |
| Recruiting |
NCT05596344 -
Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors
|
||
| Active, not recruiting |
NCT04230200 -
Prospective Screening Programme for Malignant Tumors
|
||
| Completed |
NCT04730843 -
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04952766 -
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
|
Phase 4 | |
| Recruiting |
NCT05781555 -
A Study of Diffusing Alpha Radiation Therapy for Target Treatments of Malignant Tumors
|
N/A |